Comparison Overview

Alembic Pharmaceuticals Limited

VS

Sanofi

Alembic Pharmaceuticals Limited

Alembic Road, Vadodara, 390003, IN
Last Update: 2025-12-09
View Profile
Between 750 and 799
http://www.alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,958
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Sanofi

46 Avenue de la Grande-Armée, Paris, France, 75017, FR
Last Update: 2025-12-09
Between 800 and 849
http://www.sanofi.com

We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 88,229
Subsidiaries: 6
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/alembic.jpeg
Alembic Pharmaceuticals Limited
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/sanofi.jpeg
Sanofi
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Alembic Pharmaceuticals Limited
100%
Compliance Rate
0/4 Standards Verified
Sanofi
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Alembic Pharmaceuticals Limited in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Sanofi in 2025.

Incident History — Alembic Pharmaceuticals Limited (X = Date, Y = Severity)

Alembic Pharmaceuticals Limited cyber incidents detection timeline including parent company and subsidiaries

Incident History — Sanofi (X = Date, Y = Severity)

Sanofi cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/alembic.jpeg
Alembic Pharmaceuticals Limited
Incidents

No Incident

https://images.rankiteo.com/companyimages/sanofi.jpeg
Sanofi
Incidents

No Incident

FAQ

Sanofi company demonstrates a stronger AI Cybersecurity Score compared to Alembic Pharmaceuticals Limited company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Sanofi company has disclosed a higher number of cyber incidents compared to Alembic Pharmaceuticals Limited company.

In the current year, Sanofi company and Alembic Pharmaceuticals Limited company have not reported any cyber incidents.

Neither Sanofi company nor Alembic Pharmaceuticals Limited company has reported experiencing a ransomware attack publicly.

Neither Sanofi company nor Alembic Pharmaceuticals Limited company has reported experiencing a data breach publicly.

Neither Sanofi company nor Alembic Pharmaceuticals Limited company has reported experiencing targeted cyberattacks publicly.

Neither Alembic Pharmaceuticals Limited company nor Sanofi company has reported experiencing or disclosing vulnerabilities publicly.

Neither Alembic Pharmaceuticals Limited nor Sanofi holds any compliance certifications.

Neither company holds any compliance certifications.

Sanofi company has more subsidiaries worldwide compared to Alembic Pharmaceuticals Limited company.

Sanofi company employs more people globally than Alembic Pharmaceuticals Limited company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Alembic Pharmaceuticals Limited nor Sanofi holds SOC 2 Type 1 certification.

Neither Alembic Pharmaceuticals Limited nor Sanofi holds SOC 2 Type 2 certification.

Neither Alembic Pharmaceuticals Limited nor Sanofi holds ISO 27001 certification.

Neither Alembic Pharmaceuticals Limited nor Sanofi holds PCI DSS certification.

Neither Alembic Pharmaceuticals Limited nor Sanofi holds HIPAA certification.

Neither Alembic Pharmaceuticals Limited nor Sanofi holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References